Enzymotec (ENZY) Misses Q4 EPS by 3c; Guides FY16 EPS Below Views

Enzymotec (NASDAQ: ENZY) reported Q4 EPS of $0.07, $0.03 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $13.3 million versus the consensus estimate of $14.01 million.

GUIDANCE:

Enzymotec sees FY2016 EPS of $0.25 - $0.30, versus the consensus of $0.56.

For earnings history and earnings-related data on Enzymotec (ENZY) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• The LGL Group (LGL) Misses Q2 EPS by 8c
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance